NorthWest Biotherapeutics Inc (NWBO)

[JFR161162]

Asked ChatGPT if a second CHM meeting is mandatory or not:

A second meeting with the MHRA (Medicines and Healthcare products Regulatory Agency) is not always mandatory after the initial meeting, but it often depends on the specific context of the application. Here are key points to consider:

1.
First Meeting Purpose:

The initial meeting typically serves to clarify the application process, address any questions, and confirm whether all necessary documentation and requirements have been met.

2.
Second Meeting Necessity:

•
A second meeting may be required if the MHRA needs additional information, clarification, or changes to the application.

•
It could also be necessary if the applicant requests feedback on specific issues raised during the review process.

3.
Standard Review Pathway:

•
For a standard Marketing Authorization Application (MAA), ongoing communication through written queries might suffice, without a second formal meeting.

•
For complex products, like biotech therapies, additional engagement is often encouraged to ensure alignment.

4.
Accelerated or Conditional Reviews:

•
If the product is being reviewed under an accelerated pathway (e.g., the 150-day review process), the MHRA may organize meetings to address specific concerns promptly.

•
If no major issues arise in the first meeting, a second meeting may not be required.

Ultimately, whether a second meeting is mandatory will depend on the product’s complexity, the completeness of the initial application, and any issues identified during the first meeting or subsequent review.